Journal
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
Volume 57, Issue 2, Pages 130-137Publisher
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
DOI: 10.1080/01635580701274046
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA84950, R01 CA84950S1] Funding Source: Medline
Ask authors/readers for more resources
This unblinded, randomized, Phase I clinical trial was conducted to determine whether lycopene supplementation lowered serum prostate specific antigen (PSA), surrogate endpoint for prostate cancer initiation or progression, in men with elevated prostate cancer risk. Afro-Caribbean men (n = 81) with high-grade prostatic intraepithelial neoplasia, atypical Pci or repeated non-cancerous biopsies, ascertained in a population-based screening program, were randomized to four months intervention with 30 mg/day lycopene (Lyc-O-Mato (R)) plus a multivitamin, or to multivitamin, only. Serum PSA and lycopene were compared at randomization, 1, and 4 mo using two-sided chi(2) and t-tests for independent samples. Treatment groups were similar at baseline. Serum lycopene levels approximately doubled it? the lycopene intervention group. Serum PSA declined during the first month of treatment, but returned to randomization level by month 4. The PSA response was nearly identical in both treatment groups. No adverse effects attributed to lycopene supplementation were documented. We conclude that the PSA lowering response to antioxidant supplementation observed in previous 3-wk studies in men awaiting prostatectomy may have been a transient response, perhaps not specific to lycopene. Lowering of serum PSA may not be an appropriate endpoint for) the long-term studies needed to evaluate lycopene supplementation r reducing prostate cancer initiation or progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available